Australian Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Vitrafy Life Sciences

Market Cap: AU$223.5m

Engages in the research, development, and commercialization of cryopreservation solutions in Australia.

Vita Life Sciences

Market Cap: AU$138.5m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

Firebrick Pharma

Market Cap: AU$11.1m

Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.

OncoSil Medical

Market Cap: AU$17.3m

A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.

Alterity Therapeutics

Market Cap: AU$107.7m

Engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease.

Avecho Biotechnology

Market Cap: AU$42.1m

A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India.

Clinuvel Pharmaceuticals

Market Cap: AU$451.8m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

LTR Pharma

Market Cap: AU$98.2m

A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

Immutep

Market Cap: AU$69.3m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Prescient Therapeutics

Market Cap: AU$71.5m

A clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia.

Algorae Pharmaceuticals

Market Cap: AU$22.3m

A pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.

Syntara

Market Cap: AU$45.0m

Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.

Neuren Pharmaceuticals

Market Cap: AU$1.7b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Opthea

Market Cap: AU$19.2m

A clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.

Arovella Therapeutics

Market Cap: AU$81.0m

A biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.

Medical Developments International

Market Cap: AU$43.4m

Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.

Cynata Therapeutics

Market Cap: AU$63.3m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Hexima

Market Cap: AU$2.2m

Does not have significant operations.

Aroa Biosurgery

Market Cap: AU$224.8m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Biotron

Market Cap: AU$5.4m

A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

Nexsen

Market Cap: AU$50.0m

Operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications.

Cleo Diagnostics

Market Cap: AU$69.8m

A biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.

Actinogen Medical

Market Cap: AU$122.1m

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Invex Therapeutics

Market Cap: AU$9.0m

A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

Clarity Pharmaceuticals

Market Cap: AU$800.4m

A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

Botanix Pharmaceuticals

Market Cap: AU$62.9m

Operates as a commercial dermatology company in Australia and the United States.

Patrys

Market Cap: AU$28.7m

Develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases.

Racura Oncology

Market Cap: AU$468.1m

Operates as a Phase 3 clinical biopharmaceutical company for cancer care.

Percheron Therapeutics

Market Cap: AU$6.1m

Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.

Genetic Signatures

Market Cap: AU$16.8m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Amplia Therapeutics

Market Cap: AU$56.5m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Emyria

Market Cap: AU$33.9m

Engages in delivering and developing of treatments for mental health and select neurological conditions in Australia.

Immuron

Market Cap: AU$11.1m

A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.

Tissue Repair

Market Cap: AU$6.7m

A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.

PYC Therapeutics

Market Cap: AU$1.2b

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Trajan Group Holdings

Market Cap: AU$49.6m

Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.